Percutaneous Coronary Intervention In Nstemi Patients With Heart Failure And Leukemia: Insights From The National Readmission Database

Document Type

Conference Proceeding

Publication Date

1-1-2025

Publication Title

J Card Fail

Abstract

Background: Cardiac disease is often associated with oncology patients. Our study aims to address the knowledge gap regarding the outcomes of non-ST-elevation myocardial infarction (NSTEMI) patients who have leukemia with concomitant heart failure and are undergoing percutaneous coronary intervention (PCI), providing new insights into this underexplored area. Methods: Between 2016 and 2020, we utilized the National Readmission Database to identify adult patients hospitalized for Non-ST-Elevation Myocardial Infarction (NSTEMI) who have a diagnosis heart failure and leukemia. All statistical analyses were conducted using Stata 18.0 software. Results: From our inclusion criteria, we identified 4,451 hospitalizations, of which 1,286 (28.9%) underwent PCI. The baseline patient characteristics are reported in Table 1. Compared to patients who were not re-vascularized, PCI patients were younger (median age 76 vs 79 years, p<0.05) and had a lower frailty score (median score 4.4 vs 5.6, p<0.05). Mortality was higher in patients who were not re-vascularized (no-PCI) (11.8% vs 5.6%, p<0.05). Gastrointestinal bleeding rates were similar between the two groups (7.1% vs 5.6%, p>0.05). Interestingly, acute kidney injury rates were higher in the non-PCI group (43% vs 37%,p<0.05). Conclusion: The observed higher mortality and complication rates in the non-PCI group, characterized by older age and higher frailty, underscore the impact of patient selection on treatment outcomes. This disparity highlights the complexity of managing NSTEMI patients with comorbid conditions, suggesting a need for more nuanced approaches to treatment planning and further research to optimize strategies for this high-risk population.

Volume

31

Issue

1

First Page

273

Find It @ Sladen

Share

COinS